Effect of Philadelphia Chromosome Karyotype and Allogeneic Hematopoietic Stem Cell Transplantation on Patients with Acute Lymphoblastic Leukemia.
10.19746/j.cnki.issn.1009-2137.2022.05.015
- Author:
Yang WANG
1
;
Xiao-Man XU
2
;
Min ZHANG
2
;
Hui WANG
3
Author Information
1. Department of Hematology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu Province, China.
2. Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China.
3. Department of Hematology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu Province, China,E-mail: 1919756454@qq.com.
- Publication Type:Journal Article
- Keywords:
acute lymphoblastic leukemia;
allogeneic hematopoietic stem cell transplantation;
monokaryotype;
philadelphia chromosome;
prognosis;
risk factors
- MeSH:
Acute Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Karyotype;
Philadelphia Chromosome;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2022;30(5):1397-1406
- CountryChina
- Language:Chinese
-
Abstract:
UNLABELLED:AbstractObjective: To explore the effect of Philadelphia chromosome karyotype (Ph) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) on the treatment of acute lymphoblastic leukemia (ALL).
METHODS:The data of 429 patients with all from January 2012 to December 2020 were retrospectively analyzed. According to the results of cytogenetic karyotype analysis, they were divided into Ph+ group (n=64), Ph- monomeric karyotype (MK) group (n=53) and Ph- NMK group (n=312). According to the treatment plan, they were divided into allo-HSCT group (n=236) and non-allo-HSCT group (n=193). The effects of karyotype and allo-HSCT on the short-term and long-term outcomes of all patients were analyzed.
RESULTS:Among the 429 patients, 6 (1.40%) died during induction therapy, 60 (13.99%) had no response, 363 (84.62%) achieved complete remission (CR) and 287 (66.90%) achieved minimal residual disease negative (MRD-). There was no significant difference in short-term efficacy (CR%, CR1%, MRD-%) among Ph+ group, Ph- MK group and Ph- non-MK group (P>0.05). The median OS was 6.9 months (95% CI: 4.6-8.2 months) for 60 unresponsive patients and 39.8 months (95% CI: 28.6-45.9 months) for 363 CR patients. There was no significant difference in the long-term efficacy ［5-year cumulative recurrence rate (CIR%), disease-free survival rate (DFS%) and overall survival rate (OS%) among Ph- group, Ph- MK group and Ph- non-MK group (P>0.05). Among 429 patients, 55.01% (236/429) underwent allo-HSCT. The short-term efficacy (CR%, MRD-%) and long-term efficacy (CIR%, DFS%, OS%)］ of patients with allo-HSCT after more than 2 consolidation cycles were better than those of patients with non-allo-HSCT (P<0.05). For the three subgroups of Ph+ group, Ph- MK group and Ph- non-MK group, the short-term and long-term efficacy of allo-HSCT patients was better than that of non-allo-HSCT patients. Multivariate logistic regression analysis showed that liver/spleen/lymph node enlargement was a risk factor for CIR, DFS and OS, with adjusted or of 1.23 (95% CI: 1.08-2.78, P=0.032), 1.21 (95% CI: 1.03-2.34, P=0.038) and 1.25 (95% CI: 1.08-2.97, P=0.028), respectively. No transplantation was a risk fator for CIR, DFS, OS. The adjusted or were 2.34 (95% CI: 1.18-5.39, P<0.001), 2.15 (95% CI: 1.10-4.34, P<0.001) and 2.28 (95% CI: 1.09-4.11, P<0.001), respectively.
CONCLUSION:Karyotype (Ph+/- and MK/non-MK) seems to have no effect on the short-term and long-term efficacy of all patients; allo-HSCT can affect the short-term and long-term efficacy of all patients and improve their prognosis; liver/spleen/lymph node enlargement and non-implementation of allo-HSCT treatment strategy are the risk factors for poor prognosis of all patients.
